Harte Hanks Inc (HHS) Stock Analysis

Verdict: AVOID

Shrinking revenues and a 15-month cash runway overwhelm ultra-cheap sales multiples, making debt and dilution primary equity risks.

Investment score: 38/100

Analysis as of 2026-08-22

Is Harte Hanks Inc stock worth reviewing? AI model thesis

The AI model rates HHS as AVOID due to persistent top-line erosion (-14.38% YoY) and negative FCF (-$4.49M), which leave a narrow 15-month cash runway ($5.59M cash vs $22.40M total debt).

7-factor investment score

Valuation: 45/100 (weight 20%)
Financial Health: 20/100 (weight 15%)
Technical Momentum: 55/100 (weight 15%)
Earnings Quality: 30/100 (weight 15%)
Insider Sentiment: 40/100 (weight 10%)
Analyst Consensus: 50/100 (weight 10%)
Risk-Adjusted Return: 25/100 (weight 15%)

Harte Hanks Inc opportunities and risks

What speaks for HHS

Deep Valuation Discount on Sales

What speaks against HHS

15-Month Cash Runway and Dilution Exposure

Peers and competitors

Trailing-twelve-month ratios
Ticker	P/E	P/S	EV/EBITDA	Gross margin	Net margin	FCF yield
HHS	n/a	0.2x	n/a	22.7%	-3.7%	-5.2%
MCHX	n/a	1.8x	n/a	61.2%	-12.4%	-1.9%
SCOR	0.8x	0.2x	7.9x	38.2%	-5.1%	18.1%
CREX	n/a	0.5x	n/a	41.7%	-29.3%	-28.9%
SWAG	840.9x	0.3x	21.8x	29.7%	0.0%	-11.4%
MOBQ	n/a	85.5x	n/a	-374.4%	-4070.5%	-6.1%
Peer median	n/a	0.5x	n/a	38.2%	-12.4%	-6.1%

Frequently asked questions about Harte Hanks Inc (HHS)

Is HHS stock a good investment?

The cached TradeMates AI model rates Harte Hanks Inc as AVOID with an investment score of 38/100. The AI model rates HHS as AVOID due to persistent top-line erosion (-14.38% YoY) and negative FCF (-$4.49M), which leave a narrow 15-month cash runway ($5.59M cash vs $22.40M total debt). This is algorithmic model output, not personal investment advice.

Is HHS stock a buy?

The TradeMates model verdict for HHS is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.